Today, the Ministry of Human Resources and Social Security officially issued 2017 edition of the National Reimbursement Drug List. So the adjustment plan of the National Catalogue of Medicines and Drugs reimbursement which was drawing attentions of the entire pharmaceutical industry in past two years has been released today.

Sodium hyaluronate injection from Haohai Biological Technology has been entered into 2017 edition of National Reimbursement Drug List once again after it was included in 2009 edition of National Reimbursement Drug List.

It is even more gratifying that, our Class-I new drug “recombinant human epidermal growth factor” has been limited to medication for work injury in former edition of the catalogue, but it has been adjusted to Class B medication covered by medical insurance. We believe that, the release of the application restriction over the product by the new edition will help facilitate the expansion of the product market and acquirement of more market shares.